IGF-binding Protein-2 Protects Against the Development of Obesity and Insulin Resistance

Overview

Journal Diabetes

Specialty Endocrinology

Date 2007 Jan 30

PMID 17259371

Citations 116

Authors

Stephen B Wheatcroft

Mark T Kearney

Ajay M Shah

Vivienne A Ezzat

John R Miell

Michael Modo

Stephen C R Williams

Will P Cawthorn

Gema Medina-Gomez

Antonio Vidal-Puig

Jaswinder K Sethi

Paul A Crossey

Affiliations

Soon will be listed here.

Abstract

Proliferation of adipocyte precursors and their differentiation into mature adipocytes contributes to the development of obesity in mammals. IGF-I is a potent mitogen and important stimulus for adipocyte differentiation. The biological actions of IGFs are closely regulated by a family of IGF-binding proteins (IGFBPs), which exert predominantly inhibitory effects. IGFBP-2 is the principal binding protein secreted by differentiating white preadipocytes, suggesting a potential role in the development of obesity. We have generated transgenic mice overexpressing human IGFBP-2 under the control of its native promoter, and we show that overexpression of IGFBP-2 is associated with reduced susceptibility to obesity and improved insulin sensitivity. Whereas wild-type littermates developed glucose intolerance and increased blood pressure with aging, mice overexpressing IGFBP-2 were protected. Furthermore, when fed a high-fat/high-energy diet, IGFBP-2-overexpressing mice were resistant to the development of obesity and insulin resistance. This lean phenotype was associated with decreased leptin levels, increased glucose sensitivity, and lower blood pressure compared with wild-type animals consuming similar amounts of high-fat diet. Our in vitro data suggest a direct effect of IGFBP-2 preventing adipogenesis as indicated by the ability of recombinant IGFBP-2 to impair 3T3-L1 differentiation. These findings suggest an important, novel role for IGFBP-2 in obesity prevention.

Citing Articles

IGFBP-2 in Critical Illness: A Prognostic Marker in the Growth Hormone/Insulin-like Growth Factor Axis.

Savvidis C, Kouroglou E, Kallistrou E, Ragia D, Dionysopoulou S, Gavriiloglou G Pathophysiology. 2024; 31(4):621-630.

PMID: 39585162 PMC: 11587456. DOI: 10.3390/pathophysiology31040045.

Clinical and molecular characterization of steatotic liver disease in the setting of immune-mediated inflammatory diseases.

Garcia-Nieto E, Rodriguez-Duque J, Rivas-Rivas C, Iruzubieta P, Garcia M, Rasines L JHEP Rep. 2024; 6(10):101167.

PMID: 39411649 PMC: 11474426. DOI: 10.1016/j.jhepr.2024.101167.

IGFBP2 functions as an endogenous protector against hepatic steatosis via suppression of the EGFR-STAT3 pathway.

Zhai T, Cai L, Jia X, Xia M, Bian H, Gao X Mol Metab. 2024; 89:102026.

PMID: 39299533 PMC: 11474195. DOI: 10.1016/j.molmet.2024.102026.

Prediction of gestational diabetes mellitus by multiple biomarkers at early gestation.

Yang M, Zhang L, Wang W, Huang R, He H, Zheng T BMC Pregnancy Childbirth. 2024; 24(1):601.

PMID: 39285345 PMC: 11406857. DOI: 10.1186/s12884-024-06651-4.

Effects of probiotic supplementation on circulating IGFBP-2 levels during a calorie-restricted diet in overweight humans.

Faramia J, Choi B, Brunelle L, Marette A, Drapeau V, Tremblay A J Clin Transl Endocrinol. 2024; 36:100357.

PMID: 38948244 PMC: 11211884. DOI: 10.1016/j.jcte.2024.100357.

References

Schmidt W, Loffler G . Adipose conversion of 3T3-L1 cells in a serum-free culture system depends on epidermal growth factor, insulin-like growth factor I, corticosterone, and cyclic AMP. J Biol Chem. 1990; 265(26):15489-95. View

Jitrapakdee S, Slawik M, Medina-Gomez G, Campbell M, Wallace J, Sethi J . The peroxisome proliferator-activated receptor-gamma regulates murine pyruvate carboxylase gene expression in vivo and in vitro. J Biol Chem. 2005; 280(29):27466-76. PMC: 4304003. DOI: 10.1074/jbc.M503836200. View

Crossey P, Jones J, Miell J . Dysregulation of the insulin/IGF binding protein-1 axis in transgenic mice is associated with hyperinsulinemia and glucose intolerance. Diabetes. 2000; 49(3):457-65. DOI: 10.2337/diabetes.49.3.457. View

Sjogren K, Wallenius K, Liu J, Bohlooly-Y M, Pacini G, Svensson L . Liver-derived IGF-I is of importance for normal carbohydrate and lipid metabolism. Diabetes. 2001; 50(7):1539-45. DOI: 10.2337/diabetes.50.7.1539. View

Yakar S, Wu Y, Setser J, Rosen C . The role of circulating IGF-I: lessons from human and animal models. Endocrine. 2003; 19(3):239-48. DOI: 10.1385/ENDO:19:3:239. View

Ramsay T, White M, Wolverton C . Insulin-like growth factor 1 induction of differentiation of porcine preadipocytes. J Anim Sci. 1989; 67(9):2452-9. DOI: 10.2527/jas1989.6792452x. View

Yakar S, Liu J, STANNARD B, Butler A, Accili D, Sauer B . Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A. 1999; 96(13):7324-9. PMC: 22084. DOI: 10.1073/pnas.96.13.7324. View

Sethi J, Xu H, Uysal K, Wiesbrock S, Scheja L, Hotamisligil G . Characterisation of receptor-specific TNFalpha functions in adipocyte cell lines lacking type 1 and 2 TNF receptors. FEBS Lett. 2000; 469(1):77-82. DOI: 10.1016/s0014-5793(00)01250-3. View

Hoeflich A, Wu M, Mohan S, Foll J, Wanke R, Froehlich T . Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain. Endocrinology. 1999; 140(12):5488-96. DOI: 10.1210/endo.140.12.7169. View

10.

Modric T, Silha J, Shi Z, Gui Y, Suwanichkul A, Durham S . Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice. Endocrinology. 2001; 142(5):1958-67. DOI: 10.1210/endo.142.5.8165. View

11.

Deslex S, Negrel R, Ailhaud G . Development of a chemically defined serum-free medium for differentiation of rat adipose precursor cells. Exp Cell Res. 1987; 168(1):15-30. DOI: 10.1016/0014-4827(87)90412-5. View

12.

Salih D, Tripathi G, Holding C, Szestak T, Gonzalez M, Carter E . Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice. Proc Natl Acad Sci U S A. 2004; 101(12):4314-9. PMC: 384738. DOI: 10.1073/pnas.0400230101. View

13.

Gregoire F, Smas C, Sul H . Understanding adipocyte differentiation. Physiol Rev. 1998; 78(3):783-809. DOI: 10.1152/physrev.1998.78.3.783. View

14.

Wheatcroft S, Shah A, Li J, Duncan E, Noronha B, Crossey P . Preserved glucoregulation but attenuation of the vascular actions of insulin in mice heterozygous for knockout of the insulin receptor. Diabetes. 2004; 53(10):2645-52. DOI: 10.2337/diabetes.53.10.2645. View

15.

Boney C, Stiles A, DErcole A . Expression of insulin-like growth factor-I (IGF-I) and IGF-binding proteins during adipogenesis. Endocrinology. 1994; 135(5):1863-8. DOI: 10.1210/endo.135.5.7525256. View

16.

Crossey P, Pillai C, Miell J . Altered placental development and intrauterine growth restriction in IGF binding protein-1 transgenic mice. J Clin Invest. 2002; 110(3):411-8. PMC: 151083. DOI: 10.1172/JCI10077. View

17.

Fontaine K, Redden D, Wang C, Westfall A, Allison D . Years of life lost due to obesity. JAMA. 2003; 289(2):187-93. DOI: 10.1001/jama.289.2.187. View

18.

Momin A, Melikian N, Shah A, Grieve D, Wheatcroft S, John L . Leptin is an endothelial-independent vasodilator in humans with coronary artery disease: Evidence for tissue specificity of leptin resistance. Eur Heart J. 2006; 27(19):2294-9. DOI: 10.1093/eurheartj/ehi831. View

19.

Doglio A, Dani C, Fredrikson G, Grimaldi P, Ailhaud G . Acute regulation of insulin-like growth factor-I gene expression by growth hormone during adipose cell differentiation. EMBO J. 1987; 6(13):4011-6. PMC: 553881. DOI: 10.1002/j.1460-2075.1987.tb02744.x. View

20.

Hausman D, DIGIROLAMO M, Bartness T, Hausman G, Martin R . The biology of white adipocyte proliferation. Obes Rev. 2002; 2(4):239-54. DOI: 10.1046/j.1467-789x.2001.00042.x. View